Corrigendum to “Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells” [J. Steroid Biochem. Mol. Biol. 113 (2009) 25–35] (Combination of 2-methoxyestradiol (2-ME"2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells (2009) 113(1–2) (25–35), (S0960076008002604), (10.1016/j.jsbmb.2008.11.002));Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 1-2, 2009, Pages 25-35

  Ghosh, Rita ^a   Ganapathy, Manonmani ^a   Alworth, William L ^b   Chan, Daniel C ^c   Kumar, Addanki P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Tulane University   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

2 Methoxyestradiol; Apoptosis; Combination agents; Eugenol; Mitochondrial membrane potential and prostate cancer

Indexed keywords

2 METHOXYESTRADIOL; ANDROGEN; EUGENOL; MATRIX METALLOPROTEINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 59849088724     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2021.105962     Document Type: Erratum

References (37)

1. Pienta K.J., and Smith D.C. Advances in prostate cancer therapy: a new era begins, CA. Cancer J. Clin. 55 5 (2005) 300-318
2. Dunsmuir W.D., Hrouda D., and Kirby R.S. Malignant changes in the prostate with ageing. Br. J. Urol. 82 Suppl. 1 (1998) 47-58
3. Seegers J.C., Aveling M.L., Van Aswegen C.H., Cross M., Koch F., and Joubert W.S. The cytotoxic effects of estradiol 17-β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J. Steroid Biochem. 32 6 (1989) 797-809
4. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., and Schweigerer O.L. The endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368 (1994) 237-239
5. Zhu B.T., and Conney A.H. Is 2-Methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res. 58 11 (1998) 2269-2277
6. Seeger J.C., Lottering M.-C., Grobler C.J., Van Papendorp D.H., Habbersett R.C., Shou Y., and Lehnert B.E. The mammalian metabolite 2-methoxyestradiol alters p53 levels and apoptosis induction in transformed cells. J. Steroid Biochem. Mol. Biol. 62 4 (1997) 253-267
7. Lottering M.L., Haag M., and Seegers J.C. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res. 52 21 (1997) 5926-5932
8. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J.D. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57 1 (1997) 81-86
9. Mukhopadhyay T., and Roth J.A. Super induction of wild type p53 protein after 2- methoxyestradiol treatment of Ad5p53-transduced cells induce tumor cell apoptosis. Oncogene 17 2 (1998) 241-246
10. Schumacher G., Kataoka M., Roth J.A., and Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res. 5 3 (1999) 493-499
11. Ghosh R., Ott A.M., Seetharam D., Slaga T.J., and Kumar A.P. Cell cycle block and apoptosis induction in human melanoma cell lines following treatment with 2-methoxyestradiol: therapeutic implications?. Mel. Res. 13 2 (2003) 119-127
12. Kumar A.P., Garcia G.E., Orsborn J., and Slaga T.J. 2-Methoxyestradiol interferes with NFκB transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24 2 (2003) 209-216
13. Kumar A.P., Garcia G.E., and Slaga T.J. 2-Methoxyestradiol blocks cell cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinogen. 31 3 (2001) 111-124
14. Qadan L.R., Perez-Stable C.M., Anderson C., D'Ippolito G., Herron A., Howard G.A., and Roos B.A. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate. Cancer Biochem. Biophys. Res. Commun. 285 5 (2001) 1259-1266
15. Garcia G.E., Wisniewski H.-G., Lucia M.S., Arevalo N., Slaga T.J., Kraft S.L., Strange R., and Kumar A.P. 2-Methoxyestradiol (2-ME) inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate (TRAMP): role of TNF-α stimulated gene 6 (TSG-6). Clin. Cancer Res. 12 3 (2006) 980-988
16. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., Fife K., Armstrong V., Treston A., Sidor C., and Wilding G.A. Phase II multicenter randomized, double blind, safety trial assessing the pharmacokinetic, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone refractory prostate cancer. Clin. Cancer Res. 11 18 (2005) 6625-6633
17. Sporn M.B., and Suh N. Chemoprevention of cancer. Carcinogenesis 21 3 (2000) 525-530
18. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., and Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 6 9 (2000) 1024-1028
19. Seeger H., Diesing D., Guckel B., Wallwiener D., Mueck A.O., and Huober J. Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. J. Steroid Biochem. Mol. Biol. 84 2-3 (2003) 255-257
20. Mueck A.O., Seeger H., and Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol. Life Sci. 75 10 (2004) 1205-1210
21. Han G.Z., Liu Z.J., Shimoi K., and Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule disrupting agents in human breast cancer. Cancer Res. 65 2 (2005) 387-393
22. Phillips D.H. Further evidence that eugenol does not bind to DNA in vivo. Mutat. Res. 245 1 (1990) 23-26
23. Sukumaran K., Unnikrishnan M.C., and Kuttan R. Inhibition of tumour promotion in mice by eugenol. Ind. J. Physiol. Pharmacol. 38 4 (1994) 306-308
24. Thomson D., Norbeck K., Olson L., Tesodosiu, Zee J.V., and Moldeus P. Peroxidasecatalyzed oxidation of eugenol: formation of a cytotoxic metabolite(s). J. Biol. Chem. 264 2 (1984) 1016-1021
25. Ghosh R., Nadiminty N., Fitzpatrick J.E., Alworth W.L., Slaga T.J., and Kumar A.P. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J. Biol. Chem. 280 7 (2005) 5812-5819
26. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
27. Kumar A.P., Garcia G.E., Ghosh R., Rajnarayanan R.V., Alworth W.L., and Slaga T.J. 4-Hydroxy3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NFκB cell survival signaling, pathway: potential for prostate cancer management. Neoplasia 5 3 (2003) 255-266
28. Shabbits J.A., Hu Y., and Mayer L.D. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2 8 (2003) 805-813
29. Vivanco I., and Sawyers C.L. The phosphotidylinositol-3-kinase Akt pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
30. McDonnell T.J., Navone N.M., Troncoso P., Pisters L.L., Conti C., Von Eschenbach A.C., Brisbay S., and Logothetis C.J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. 157 2 (1997) 569-574
31. Tu S.M., McConnell K., Marin M.C., Campbell M.L., Fernandez A., Von Eschenbach A.C., and McDonnell T.J. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett. 93 2 (1995) 147-155
32. Lisa F.D., Blank P.S., Colonna R., Gambassi G., Silverman H.S., Stern M.D., and Hansford R.G. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J. Physiol. 486 1 (1995) 1-13
33. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
34. Cossarizza A., Baccarani-Contri M., Kalashnikova G., and Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol carbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 197 1 (1993) 40-45
35. Cao W., Yacoub S., Shiverick K.T., Namiki K., Sakai Y., Porvasnik S., Urbanek C., and Rosser C.J. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. The Prostate 68 11 (2008) 1223-1231
36. Jiang S., Zu Y., Fu Y., Zhang Y., and Efferth T. Activation of mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int. J. Oncol. 33 1 (2008) 103-111
37. N. Xiang, R. Zhao, W. Zhong, Sodium Selenite induces apoptosis by generation of superoxide via the mitochondrial dependent pathway in human prostate cancer cells, Cancer Chemother. Pharmacol., 2008, April 1 [Epub ahead of print].